2PQ Stock Overview
A regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Organogenesis Holdings Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$4.52 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$2.06 |
| Beta | 1.66 |
| 1 Month Change | 29.14% |
| 3 Month Change | 49.67% |
| 1 Year Change | 77.95% |
| 3 Year Change | -30.99% |
| 5 Year Change | 49.67% |
| Change since IPO | -40.29% |
Recent News & Updates
Recent updates
Shareholder Returns
| 2PQ | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -6.2% | 3.4% | 4.1% |
| 1Y | 78.0% | -10.0% | 17.2% |
Return vs Industry: 2PQ exceeded the German Biotechs industry which returned -10% over the past year.
Return vs Market: 2PQ exceeded the German Market which returned 17.2% over the past year.
Price Volatility
| 2PQ volatility | |
|---|---|
| 2PQ Average Weekly Movement | 20.5% |
| Biotechs Industry Average Movement | 9.2% |
| Market Average Movement | 5.4% |
| 10% most volatile stocks in DE Market | 12.1% |
| 10% least volatile stocks in DE Market | 2.8% |
Stable Share Price: 2PQ's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: 2PQ's weekly volatility has increased from 14% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 869 | Gary Gillheeney | organogenesis.com |
Organogenesis Holdings Inc., a regenerative medicine company, develops, manufactures, and commercializes products for the advanced wound care, and surgical and sports medicine markets in the United States. The company’s advanced wound care products include Affinity and Novachor, which are amnion and chorion placental allografts for use in the care of chronic and acute wounds as protective barriers and extracellular matrix (ECM) scaffolds; Apligraf, a bioengineered bi-layered skin substitute for the treatment of venous leg ulcers and diabetic foot ulcers (DFU); Dermagraft, a dermal substitute grown from human dermal fibroblasts to treat DFUs; NuShield, a dehydrated placental allograft and surgical barrier to provide a protective barrier and ECM scaffold to support native healing; PuraPly Antimicrobial (AM) and PuraPly SX, which are antimicrobial barriers for the management of open wounds in surgical settings; and CYGNUS Dual, a dual-layered amniotic tissue graft used to treat chronic and acute wounds. It also provides PuraPly MZ, a micronized version of PuraPly for the management of open wounds in surgical settings; FortiShield, a biosynthetic wound matrix for use as a temporary protective covering; TransCyte, a bioengineered tissue scaffold that promotes burn healing; and PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications.
Organogenesis Holdings Inc. Fundamentals Summary
| 2PQ fundamental statistics | |
|---|---|
| Market cap | €578.13m |
| Earnings (TTM) | -€855.95k |
| Revenue (TTM) | €440.35m |
1.3x
P/S Ratio-675.4x
P/E RatioIs 2PQ overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 2PQ income statement (TTM) | |
|---|---|
| Revenue | US$482.04m |
| Cost of Revenue | US$115.74m |
| Gross Profit | US$366.30m |
| Other Expenses | US$367.24m |
| Earnings | -US$937.00k |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.0074 |
| Gross Margin | 75.99% |
| Net Profit Margin | -0.19% |
| Debt/Equity Ratio | 0% |
How did 2PQ perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/03/19 13:31 |
| End of Day Share Price | 2025/03/18 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Organogenesis Holdings Inc. is covered by 9 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Michael Gorman | BTIG |
| Ross Osborn | Cantor Fitzgerald & Co. |
| Matthew Miksic | Credit Suisse |